Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative.

National Institute of Mental Health, Bethesda, MD 20892, USA.
Archives of general psychiatry (Impact Factor: 12.26). 03/2011; 68(3):241-51. DOI: 10.1001/archgenpsychiatry.2011.12
Source: PubMed

ABSTRACT There is limited information on the prevalence and correlates of bipolar spectrum disorder in international population-based studies using common methods.
To describe the prevalence, impact, patterns of comorbidity, and patterns of service utilization for bipolar spectrum disorder (BPS) in the World Health Organization World Mental Health Survey Initiative.
Cross-sectional, face-to-face, household surveys of 61,392 community adults in 11 countries in the Americas, Europe, and Asia assessed with the World Mental Health version of the World Health Organization Composite International Diagnostic Interview, version 3.0, a fully structured, lay-administered psychiatric diagnostic interview.
Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) disorders, severity, and treatment.
The aggregate lifetime prevalences were 0.6% for bipolar type I disorder (BP-I), 0.4% for BP-II, 1.4% for subthreshold BP, and 2.4% for BPS. Twelve-month prevalences were 0.4% for BP-I, 0.3% for BP-II, 0.8% for subthreshold BP, and 1.5% for BPS. Severity of both manic and depressive symptoms as well as suicidal behavior increased monotonically from subthreshold BP to BP-I. By contrast, role impairment was similar across BP subtypes. Symptom severity was greater for depressive episodes than manic episodes, with approximately 74.0% of respondents with depression and 50.9% of respondents with mania reporting severe role impairment. Three-quarters of those with BPS met criteria for at least 1 other disorder, with anxiety disorders (particularly panic attacks) being the most common comorbid condition. Less than half of those with lifetime BPS received mental health treatment, particularly in low-income countries, where only 25.2% reported contact with the mental health system.
Despite cross-site variation in the prevalence rates of BPS, the severity, impact, and patterns of comorbidity were remarkably similar internationally. The uniform increases in clinical correlates, suicidal behavior, and comorbidity across each diagnostic category provide evidence for the validity of the concept of BPS. Treatment needs for BPS are often unmet, particularly in low-income countries.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Link to this article: How to cite this article: C. Fagnani, M. Bellani, J. C. Soares, M. A. Stazi and P. Brambilla Discordant twins as a tool to unravel the aetiology of bipolar disorder. Epidemiology and Psychiatric Sciences, Available on CJO 2014
    Epidemiology and Psychiatric Sciences 03/2014; · 3.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bipolar disorder (BD) is a debilitating mental disorder. However, there are no biomarkers available to support objective laboratory testing for this disorder. Here, a nuclear magnetic resonance spectroscopy-based metabonomic method was used to characterize the urinary metabolic profiling of BD subjects and healthy controls in order to identify and validate urinary metabolite biomarkers for BD. Four metabolites, α-hydroxybutyrate, choline, isobutyrate, and N-methylnicotinamide, were defined as biomarkers. A combined panel of these four urinary metabolites could effectively discriminate between BD subjects and healthy controls, achieving an area under the receiver operating characteristic curve (AUC) of 0.89 in a training set (n = 60 BD patients and n = 62 controls). Moreover, this urinary biomarker panel was capable of discriminating blinded test samples (n = 26 BD patients and n = 34 controls) with an AUC of 0.86. These findings suggest that a urine-based laboratory test using these biomarkers may be useful in the diagnosis of BD.
    Metabolomics 08/2013; 9(4):800-808. · 3.97 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: First episode mania (FEM) cohorts provide an opportunity to identify windows for intervention to potentially alter the course of bipolar disorder (BD). Despite several efforts to prospectively characterize first episode patients, follow-up of such cohorts has seldom exceeded 1 year. We present 4-year outcomes from the STOP-EM FEM cohort. Of 101 identified FEM patients, 81 had longitudinal follow-up. Clinical evaluations including substance misuse, sociodemographics and family history were characterized using semi-structured instruments. Clinical reassessments occurred every 6 months. Within one year, all patients had remitted and 95% recovered. Recurrence following remission occurred in 58% of patients by 1 year and 74% by 4 years (60% depressive, 28% manic and 12% hypomanic). Recurrence within one year was associated with a higher rate of recurrence thereafter. Older age was associated with a shorter time to remission. Substance misuse was associated with delayed recovery and earlier recurrence. This prospective multiwave longitudinal design employed may be limited by the assessment schedule and associated recall bias. The influences of attrition of this sample should be considered when attempting to generalize our findings. Best practices in FEM result in remission and recovery. While recurrence is common, minimizing recurrence within the first year through risk factor modification may alter the course of the BD. Copyright © 2015 Elsevier B.V. All rights reserved.
    Journal of Affective Disorders 01/2015; 175C:411-417. · 3.76 Impact Factor


Available from
May 19, 2014